See the DrugPatentWatch profile for hycamtin
Is Hycamtin Approved for Small Cell Lung Cancer?
Yes, Hycamtin (topotecan hydrochloride) is FDA-approved for treating small cell lung cancer (SCLC). It is indicated for relapsed SCLC sensitive to initial chemotherapy or for patients who progressed at least 60 days after completing first-line therapy.[1]
How Is Hycamtin Used in SCLC Treatment?
Hycamtin is given intravenously, typically as 1.5 mg/m² once daily for 5 consecutive days, repeated every 21 days. It targets topoisomerase I, an enzyme cancer cells need to divide, which is effective in platinum-sensitive relapsed SCLC. Clinical trials showed response rates of 15-24% in this setting.[1][2]
When Is It Recommended for SCLC Patients?
Guidelines from the National Comprehensive Cancer Network (NCCN) recommend Hycamtin as a second-line option for sensitive relapsed SCLC, alongside alternatives like irinotecan or lurbinectedin. It is not first-line due to lower efficacy compared to platinum-etoposide regimens.[3]
What About Oral Hycamtin Capsules?
The oral capsule form (marketed as Hycamtin Capsules) is also FDA-approved specifically for relapsed SCLC after platinum-based therapy, offering convenience over IV with similar efficacy in trials.[1]
Common Side Effects in SCLC Patients
Patients report bone marrow suppression (neutropenia in 60-70%, anemia, thrombocytopenia), nausea, fatigue, and infections. Dose reductions occur in about 30% of cases due to toxicity.[1][2]
How Does Hycamtin Compare to Other SCLC Drugs?
| Drug | Use in SCLC | Response Rate (Relapsed) | Key Difference |
|------|-------------|---------------------------|---------------|
| Hycamtin | Second-line, sensitive relapse | 15-24% | IV/oral options; higher myelosuppression |
| Irinotecan | Second-line | 10-20% | Often combined; less bone marrow toxicity |
| Lurbinotecedin | Second-line | 35% | Newer approval; targets transcription |
| Topotecan + Atezolizumab | Investigational combos | Up to 50% in trials | Immunotherapy boost |
Hycamtin remains a standard but is often edged out by newer agents in guidelines.[3]
Patent and Availability Details
Hycamtin's key patents have expired, allowing generics. Check DrugPatentWatch.com for exact expiration dates and generic entrants, which improve access and lower costs.[4]
[1] FDA Label: Hycamtin (topotecan) - https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020971s034lbl.pdf
[2] Eckardt JR et al., J Clin Oncol (2006) - Topotecan in relapsed SCLC
[3] NCCN Guidelines: Small Cell Lung Cancer (Version 3.2023) - https://www.nccn.org/guidelines
[4] DrugPatentWatch.com - Hycamtin patents - https://www.drugpatentwatch.com/p/tradename/HYCAMTIN